SELLAS Life Sciences (SLS) Cash & Equivalents (2010 - 2026)

SELLAS Life Sciences (SLS) has 17 years of Cash & Equivalents data on file, last reported at $107.1 million in Q1 2026.

• On a quarterly basis, Cash & Equivalents rose 107000.0% year-over-year to $107.1 million in Q1 2026; TTM through Mar 2026 was $107.1 million, a 107000.0% increase from a year earlier, with the FY2025 full-year figure at $100000.0, down 99.28% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $107.1 million, up from $100000.0 in the prior quarter.
• Over the last five years, Cash & Equivalents for SLS reached as high as $107.1 million in Q1 2026 and fell as low as $100000.0 in Q1 2022.
• Historically, Cash & Equivalents has averaged $15.7 million across 5 years, with a median of $4.0 million in 2023.
• Across the five-year window, Cash & Equivalents tumbled 99.62% in 2022 and jumped 107000.0% in 2026, its largest moves.
• Year by year, Cash & Equivalents stood at $17.1 million in 2022, then slumped by 99.42% to $100000.0 in 2023, then jumped by 13786.0% to $13.9 million in 2024, then tumbled by 99.28% to $100000.0 in 2025, then soared by 107000.0% to $107.1 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $107.1 million in Q1 2026, $100000.0 in Q4 2025, and $44.3 million in Q3 2025.